MetaADEDB 2.0 @ LMMD
Cromolyn Sodium
(IMZMKUWMOSJXDT-UHFFFAOYSA-N)
Structure
SMILES
OC(COc1cccc2c1c(=O)cc(o2)C(=O)O)COc1cccc2c1c(=O)cc(o2)C(=O)O
Type(s)
Approved
ATC code(s)
A07EB01; D11AH03; R01AC01; R01AC51; R03AK04; R03AK05; R03BC01; S01GX01; S01GX51
Molecular Formula:
C23H16O11
Molecular Weight:
468.367
Log P:
2.1145
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
3
TPSA:
173.71
CAS Number(s):
16110-51-3
Synonym(s)
1.
Cromolyn Sodium
2.
Disodium Cromoglycate
3.
Sodium Cromoglycate
4.
Aarane
5.
Bicromat Spray
6.
Cromoglicic Acid
7.
Cromoglycate
8.
Cromoglycic Acid
9.
Cromolyn
10.
FPL-670
11.
Intal
12.
Lomudal
13.
Nalcrom
14.
Nasalcrom
15.
Opticrom
16.
Vicrom
17.
Acid, Cromoglicic
18.
Acid, Cromoglycic
19.
Cromoglycate, Disodium
20.
Cromoglycate, Sodium
21.
FPL 670
22.
FPL670
External Link(s)
MeSHD004205
PubChem Compound2882
BindingDB50440033
ChEBI59773
CHEMBLCHEMBL428880
DrugBankDB01003
DrugCentral741
IUPHAR/BPS Guide to PHARMACOLOGY7608
KEGGcpd:C06928
dr:D07753
Therapeutic Target DatabaseD0G7IY
D0B9GH
ZINC1530788
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1DysphoniaFAERS: 2OFFSIDES
US FAERS
2Abdominal discomfortFAERS: 1US FAERS
3AcneFAERS: 1US FAERS
4CheilitisFAERS: 1US FAERS
5Chest PainFAERS: 1US FAERS
6ChokingFAERS: 1US FAERS
7DizzinessFAERS: 1OFFSIDES
US FAERS
8Drug dose omissionFAERS: 1US FAERS
9Drug ineffectiveFAERS: 1US FAERS
10ErythemaFAERS: 1US FAERS
11ExcoriationFAERS: 1US FAERS
12Expired product administeredFAERS: 1US FAERS
13Exposure to toxic agentFAERS: 1US FAERS
14Feeling abnormalFAERS: 1US FAERS
15HeadacheFAERS: 1US FAERS
16HypersensitivityFAERS: 1US FAERS
17Inappropriate schedule of drug administrationFAERS: 1US FAERS
18Intentional product use issueFAERS: 1US FAERS
19Irritable Bowel SyndromeFAERS: 1US FAERS
20Lip exfoliationFAERS: 1US FAERS
21Lip swellingFAERS: 1US FAERS
22MalaiseFAERS: 1US FAERS
23MyalgiaFAERS: 1US FAERS
24NauseaFAERS: 1
Canada Vigilance: 1		Canada Vigilance
OFFSIDES
US FAERS
25PainFAERS: 1US FAERS
26PalpitationsFAERS: 1US FAERS
27Product use in unapproved indicationFAERS: 1US FAERS
28Respiratory tract irritationFAERS: 1OFFSIDES
US FAERS
29Secretion dischargeFAERS: 1US FAERS
30SneezingFAERS: 1US FAERS
31Therapeutic response unexpectedFAERS: 1US FAERS
32Wrong technique in drug usage processFAERS: 1US FAERS
33AbscessOFFSIDES
34Adverse eventOFFSIDES
35AlopeciaOFFSIDES
36AlveolitisOFFSIDES
37AmnesiaOFFSIDES
38Amniotic cavity disorderOFFSIDES
39AmphetaminesOFFSIDES
40ApathyOFFSIDES
41Application site erythemaOFFSIDES
42Application site pruritusOFFSIDES
43Application site vesiclesOFFSIDES
44ArthritisOFFSIDES
45AsphyxiaOFFSIDES
46AsthmaOFFSIDES
47Atrial FlutterOFFSIDES
48Atrial tachycardiaOFFSIDES
49AutomatismOFFSIDES
50BedriddenOFFSIDES
51Blood GlucoseOFFSIDES
52Blood corticotrophinOFFSIDES
53Blood creatine phosphokinase increasedOFFSIDES
54Blood glucose abnormalOFFSIDES
55Blood immunoglobulin G abnormalOFFSIDES
56Blood lactate dehydrogenase increasedOFFSIDES
57Blood potassium increasedOFFSIDES
58Blood uric acidOFFSIDES
59Bone density decreasedOFFSIDES
60Bone marrow depressionOFFSIDES
61Bone painOFFSIDES
62BronchiectasisOFFSIDES
63BronchitisOFFSIDES
64Catheter related complicationOFFSIDES
65Choking sensationOFFSIDES
66Chronic Obstructive Airway DiseaseOFFSIDES
67Circumstance or information capable of leading to medication errorOFFSIDES
68Cognitive deteriorationOFFSIDES
69Compression fractureOFFSIDES
70DemyelinationOFFSIDES
71Dental cariesOFFSIDES
72Deposit eyeOFFSIDES
73DiarrheaOFFSIDES
74Diastolic dysfunctionOFFSIDES
75Disease recurrenceOFFSIDES
76Drug DependenceCanada Vigilance: 1Canada Vigilance
77DysmorphismOFFSIDES
78DyspepsiaCanada Vigilance: 1Canada Vigilance
79Ear discomfortOFFSIDES
80Epidermal necrosisOFFSIDES
81EpistaxisOFFSIDES
82Expired drug administeredOFFSIDES
83FlushingCanada Vigilance: 2Canada Vigilance
84GastritisCanada Vigilance: 1Canada Vigilance
85GlaucomaOFFSIDES
86Granulocyte count decreasedOFFSIDES
87HyperkeratosisOFFSIDES
88HypophagiaOFFSIDES
89HysterectomyOFFSIDES
90Incision site complicationOFFSIDES
91IncontinenceOFFSIDES
92Infusion site reactionOFFSIDES
93Inhalation TherapyOFFSIDES
94Injection site erythemaOFFSIDES
95Injection site urticariaOFFSIDES
96Leukopenia neonatalOFFSIDES
97Lymphocyte stimulation test positiveOFFSIDES
98Lymphocytic infiltrationOFFSIDES
99Malignant neoplasm of spinal cordOFFSIDES
100Mental impairmentOFFSIDES
101MorpheaOFFSIDES
102Muscle tightnessOFFSIDES
103Musculoskeletal discomfortOFFSIDES
104Nasal discomfortOFFSIDES
105Nasal inflammationOFFSIDES
106Nephrotic SyndromeOFFSIDES
107NocturiaOFFSIDES
108Obsessive thoughtsOFFSIDES
109OliguriaOFFSIDES
110Optic Disc EdemaOFFSIDES
111Oral mucosal exfoliationOFFSIDES
112Oropharyngeal painOFFSIDES
113OsteopeniaOFFSIDES
114OsteoporosisOFFSIDES
115OverdoseOFFSIDES
116PallorOFFSIDES
117Pancreatic enzymes abnormalOFFSIDES
118PemphigusOFFSIDES
119PneumothoraxOFFSIDES
120PolyuriaOFFSIDES
121Procedural complicationOFFSIDES
122Psychomotor skills impairedOFFSIDES
123Pulmonary congestionOFFSIDES
124Reaction to preservativesOFFSIDES
125ScotomaOFFSIDES
126Self MutilationOFFSIDES
127Shoulder PainOFFSIDES
128Sinus headacheOFFSIDES
129Skin lesionOFFSIDES
130Spinal column stenosisOFFSIDES
131Sudden Cardiac DeathOFFSIDES
132TalipesOFFSIDES
133ThyroiditisOFFSIDES
134Tongue exfoliationOFFSIDES
135UrticariaCanada Vigilance: 2Canada Vigilance
136Venoocclusive diseaseOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120238

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.